Stay updated on Cabozantinib in HR+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib in HR+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib in HR+ Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.5.3 to v3.5.4, indicating a newer document revision. This is a minor metadata update and does not alter the study content visible to users.
    Difference
    0.1%
    Check dated 2026-05-17T10:25:41.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    The page’s displayed site revision/version was updated from v3.5.2 to v3.5.3.
    Difference
    0.1%
    Check dated 2026-04-25T18:47:45.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-18T13:48:00.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    Revision note updated to v3.5.0, replacing the previous v3.4.3 entry.
    Difference
    0.1%
    Check dated 2026-03-21T01:18:13.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Revision updated to v3.4.3. The prior revision v3.4.2 was removed.
    Difference
    0.1%
    Check dated 2026-03-06T18:11:24.000Z thumbnail image
  9. Check
    105 days ago
    Change Detected
    Summary
    Revision: v3.4.2 replaces v3.4.1 on the page, reflecting an internal update. No user-facing content or functionality appears to be affected.
    Difference
    0.1%
    Check dated 2026-02-13T12:39:17.000Z thumbnail image

Stay in the know with updates to Cabozantinib in HR+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib in HR+ Breast Cancer Clinical Trial page.